Skip to main content

01.10.2007 | Breast Oncology

Treatment Trends and Factors Associated with Survival in T1aN0 and T1bN0 Breast Cancer Patients

verfasst von: Timothy Kennedy, MD, Andrew K. Stewart, MA, Karl Y. Bilimoria, MD, Lina Patel-Parekh, MHA, Stephen F. Sener, MD, David P. Winchester, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Breast conservation therapy (BCT) and adjuvant hormonal therapy for estrogen-receptor positive breast cancers have become standard of care. Our objectives were to evaluate trends in the surgical management and adjuvant therapy for early-stage breast cancer and to identify factors predicting survival.

Methods

Using the National Cancer Data Base (NCDB), patients with node-negative breast cancers less than 1 cm (T1aN0M0 and T1bN0M0) from 1993–2004 were identified. The time periods of 1993–1994, 1998–1999, and 2003–2004 were compared to analyze trends in surgical management and adjuvant therapy. Cox Proportional Hazards modeling was used to examine factors predicting survival.

Results

Overall, 123,212 cases of T1aN0M0 or T1bN0M0 breast cancer were identified. The use of breast conservation surgery increased from 61.3% in 1993/1994 to 78.3% in 2003/2004 with a concomitant decrease in the use of mastectomy. The use of radiation therapy also increased from 51.9% in 1993/1994 to 62.0% in 2003/2004. Adjuvant hormonal therapy administration rose sharply from 26.7% in 1993/1994 to 44.7% in 2003/2004. After adjusting for potential confounders, the difference in 5-year survival rates for T1a (94.3%) and T1b (93.1%) tumors was marginal (P = .04). Age, grade, size, and failure of BCS patients to receive radiation therapy and hormonal therapy were independent predictors of a higher likelihood of death.

Conclusions

BCS utilization increased over time, but mastectomy rates may still be considered high given the small size of tumors in this cohort and the percent of patients eligible for BCT. The use of hormonal therapy increased significantly over the past decade. Further investigation into patient and physician factors affecting treatment choices is needed if BCT and hormonal therapy utilization is to increase.
Literatur
2.
Zurück zum Zitat Edwards BK, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97(19):1407–27PubMedCrossRef Edwards BK, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97(19):1407–27PubMedCrossRef
3.
Zurück zum Zitat Bland KI, et al. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer 1998; 83(6):1262–73PubMedCrossRef Bland KI, et al. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer 1998; 83(6):1262–73PubMedCrossRef
4.
Zurück zum Zitat Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347(16):1233–41PubMedCrossRef Fisher B, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347(16):1233–41PubMedCrossRef
5.
Zurück zum Zitat Veronesi U, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347(16):1227–32PubMedCrossRef Veronesi U, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347(16):1227–32PubMedCrossRef
6.
Zurück zum Zitat NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991; 265(3):391–5CrossRef NIH consensus conference. Treatment of early-stage breast cancer. JAMA 1991; 265(3):391–5CrossRef
7.
Zurück zum Zitat Eifel P, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst 2001; 93(13):979–89PubMedCrossRef Eifel P, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst 2001; 93(13):979–89PubMedCrossRef
8.
Zurück zum Zitat Michaelson JS, et al. Gauging the impact of breast carcinoma screening in terms of tumor size and death rate. Cancer 2003; 98(10):2114–24PubMedCrossRef Michaelson JS, et al. Gauging the impact of breast carcinoma screening in terms of tumor size and death rate. Cancer 2003; 98(10):2114–24PubMedCrossRef
9.
Zurück zum Zitat Smith RA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003; 53(3):141–69PubMed Smith RA, et al. American Cancer Society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 2003; 53(3):141–69PubMed
10.
Zurück zum Zitat Elkin EB, et al. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975–1999. Cancer 2005; 104(6):1149–57PubMedCrossRef Elkin EB, et al. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975–1999. Cancer 2005; 104(6):1149–57PubMedCrossRef
11.
Zurück zum Zitat Winchester DP, Cox JD. Standards for diagnosis and management of invasive breast carcinoma. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology. CA Cancer J Clin 1998; 48(2):83–107PubMedCrossRef Winchester DP, Cox JD. Standards for diagnosis and management of invasive breast carcinoma. American College of Radiology. American College of Surgeons. College of American Pathologists. Society of Surgical Oncology. CA Cancer J Clin 1998; 48(2):83–107PubMedCrossRef
12.
Zurück zum Zitat Al-Refaie W, et al. Determinants of mastectomy in breast conservation therapy candidates. Am J Surg 2005; 190(4):602–5PubMedCrossRef Al-Refaie W, et al. Determinants of mastectomy in breast conservation therapy candidates. Am J Surg 2005; 190(4):602–5PubMedCrossRef
13.
Zurück zum Zitat Morrow M, Bucci C, Rademaker A. Medical contraindications are not a major factor in the underutilization of breast conserving therapy. J Am Coll Surg, 1998; 186(3):269–74CrossRef Morrow M, Bucci C, Rademaker A. Medical contraindications are not a major factor in the underutilization of breast conserving therapy. J Am Coll Surg, 1998; 186(3):269–74CrossRef
14.
Zurück zum Zitat Lazovich D, et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer 1999; 86(4):628–37PubMedCrossRef Lazovich D, et al. Breast conservation therapy in the United States following the 1990 National Institutes of Health Consensus Development Conference on the treatment of patients with early stage invasive breast carcinoma. Cancer 1999; 86(4):628–37PubMedCrossRef
15.
Zurück zum Zitat McCloskey SA, et al. Long-term outcomes after breast conservation therapy for early stage breast cancer in a community setting. Breast J 2006; 12(2):138–44PubMedCrossRef McCloskey SA, et al. Long-term outcomes after breast conservation therapy for early stage breast cancer in a community setting. Breast J 2006; 12(2):138–44PubMedCrossRef
16.
Zurück zum Zitat Morris CR, et al. Increasing trends in the use of breast-conserving surgery in California. Am J Public Health 2000; 90(2):281–4PubMedCrossRef Morris CR, et al. Increasing trends in the use of breast-conserving surgery in California. Am J Public Health 2000; 90(2):281–4PubMedCrossRef
17.
Zurück zum Zitat Polednak AP. Trends in, and predictors of, breast-conserving surgery and radiotherapy for breast cancer in Connecticut, 1988–1997. Int J Radiat Oncol Biol Phys 2002; 53(1):157–63PubMedCrossRef Polednak AP. Trends in, and predictors of, breast-conserving surgery and radiotherapy for breast cancer in Connecticut, 1988–1997. Int J Radiat Oncol Biol Phys 2002; 53(1):157–63PubMedCrossRef
18.
Zurück zum Zitat Nakhlis F, et al. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. J Am Coll Surg 2005; 201(5):688–94PubMedCrossRef Nakhlis F, et al. Tamoxifen use in patients with ductal carcinoma in situ and T1a/b N0 invasive carcinoma. J Am Coll Surg 2005; 201(5):688–94PubMedCrossRef
19.
Zurück zum Zitat Port ER, et al. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001; 8(7):580–5PubMedCrossRef Port ER, et al. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001; 8(7):580–5PubMedCrossRef
20.
Zurück zum Zitat Malin JL, et al. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 2002; 94(11):835–44PubMed Malin JL, et al. Validity of cancer registry data for measuring the quality of breast cancer care. J Natl Cancer Inst 2002; 94(11):835–44PubMed
21.
Zurück zum Zitat National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr 2001; (30):5–15 National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst Monogr 2001; (30):5–15
22.
Zurück zum Zitat Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472):1687–717CrossRef Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472):1687–717CrossRef
23.
Zurück zum Zitat Mann GB, et al. Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma. Ann Surg Oncol 1999; 6(6):591–8PubMedCrossRef Mann GB, et al. Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma. Ann Surg Oncol 1999; 6(6):591–8PubMedCrossRef
24.
Zurück zum Zitat Reed W, et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14–30 years. Cancer 2000; 88(4):804–13PubMedCrossRef Reed W, et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14–30 years. Cancer 2000; 88(4):804–13PubMedCrossRef
25.
Zurück zum Zitat Mirza AN, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235(1):10–26PubMedCrossRef Mirza AN, et al. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 2002; 235(1):10–26PubMedCrossRef
26.
Zurück zum Zitat Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63(1):181–7PubMedCrossRef Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63(1):181–7PubMedCrossRef
27.
Zurück zum Zitat Rosen PP, et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993; 11(11):2090–100PubMed Rosen PP, et al. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993; 11(11):2090–100PubMed
28.
Zurück zum Zitat Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat 2005; 89(1):47–54PubMedCrossRef Rosenberg J, Chia YL, Plevritis S. The effect of age, race, tumor size, tumor grade, and disease stage on invasive ductal breast cancer survival in the U.S. SEER database. Breast Cancer Res Treat 2005; 89(1):47–54PubMedCrossRef
29.
Zurück zum Zitat Rosen PR, et al. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989; 7(3):355–66PubMed Rosen PR, et al. A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 1989; 7(3):355–66PubMed
30.
Zurück zum Zitat Saimura M, et al. Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor. J Surg Oncol 1999; 71(2):101–5PubMedCrossRef Saimura M, et al. Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor. J Surg Oncol 1999; 71(2):101–5PubMedCrossRef
31.
Zurück zum Zitat Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994; (16):35–42PubMed Albain KS, Allred DC, Clark GM. Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst Monogr 1994; (16):35–42PubMed
32.
Zurück zum Zitat Jayasinghe UW, Taylor R, Boyages J. Is age at diagnosis an independent prognostic factor for survival following breast cancer? ANZ J Surg 2005; 75(9):762–7PubMedCrossRef Jayasinghe UW, Taylor R, Boyages J. Is age at diagnosis an independent prognostic factor for survival following breast cancer? ANZ J Surg 2005; 75(9):762–7PubMedCrossRef
33.
Zurück zum Zitat Nixon AJ, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994; 12(5):888–94PubMed Nixon AJ, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 1994; 12(5):888–94PubMed
Metadaten
Titel
Treatment Trends and Factors Associated with Survival in T1aN0 and T1bN0 Breast Cancer Patients
verfasst von
Timothy Kennedy, MD
Andrew K. Stewart, MA
Karl Y. Bilimoria, MD
Lina Patel-Parekh, MHA
Stephen F. Sener, MD
David P. Winchester, MD
Publikationsdatum
01.10.2007
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 10/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9441-5

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.